XM does not provide services to residents of the United States of America.
S
S

Straumann

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

STOXX 600 falls on earnings drag, travel and leisure worst hit

UPDATE 2-STOXX 600 falls on earnings drag, travel and leisure worst hit For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window BP shares touch July 2022 lows HSBC rises after Q3 profit beat, share buyback plan Lufthansa slides on lower Q3 profit Adidas rises on 'generally positive' Q3 details, China strength STOXX 600 down 0.6% Updates with closing levels By Ankika Biswas and Pranav Kashyap Oct 29 (Reuters) - Europe's main stock index dropped o
A
A
B
G
H
L
M
N
O
S
S
W
E
F
U
G

Straumann fall premarket as Q3 result weighed by weak US performance

BUZZ-Straumann fall premarket as Q3 result weighed by weak US performance ** Shares in Swiss dental implant maker Straumann STMN.S are seen down 2.4% in Julius Baer's premarket indicator after the company released third-quarter sales report ** Sales were in line with estimates, Vontobel analysts say, but point out that the 2% growth in the U.S. was
S
J

Straumann's sales rise, boosted by strong demand in Asia-Pacific

UPDATE 2-Straumann's sales rise, but weak North America drags shares Adds shares in paragraph 2, analyst and trader comments in paragraphs 3, 4, 10 By Alberto Chiumento Oct 29 (Reuters) - Swiss dental implants maker Straumann STMN.S on Tuesday reported double-digit percentage growth in its organic revenue for the third quarter, as more people sought dental services around the world, and especially in the Asia-Pacific.
S

Straumann's sales rise, boosted by strong demand in Asia-Pacific

Straumann's sales rise, boosted by strong demand in Asia-Pacific Oct 28 (Reuters) - Swiss dental implants maker Straumann STMN.S on Tuesday reported a double-digit percentage rise in its organic revenue for the third quarter, as more people sought dental services around the world, especially in the Asia-Pacific region. Revenue grew to 585.5 million Swiss Francs ($676.6 million) in the quarter, up 11.2% when excluding currency exchange effects and acquisitions.
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.